Trials
2 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Advanced Solid Tumors, Hepatocellular Carcinoma
- Main trialPhase 1/2
- “The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG006A in patients with advanced solid tumors.”In the company’s words, NCT07093970 on ClinicalTrials.gov
Other drugs for Advanced Solid Tumors
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up2
- Dec 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Apr 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Dec 2027 | A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors | |
| Phase 1/2Recruiting | Apr 2028 | MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026